GlassScriptPhysician profile
Francis A Robichaux
NPI 1528051794
$6,914.57
in general payments reported to CMS, 2019-2025
41 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $432 · 2021: $923 · 2022: $1,257 · 2023: $1,277 · 2024: $925 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.82 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $879.85 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $842.46 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $598.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $595.24 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $419.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $264.94 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $165.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.76 | 2019-2025 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $148.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $132.26 | 2019-2023 | Steglatro, Belsomra |
| Kowa Pharmaceuticals America, INC. | $120.65 | 2019-2025 | Zoryve, Livalo |
| Amarin Pharma, INC. | $102.39 | 2019-2022 | |
| Astellas Pharma US INC | $80.36 | 2019-2023 | Veozah |
| Ironwood Pharmaceuticals, INC | $77.08 | 2020-2023 | Linzess |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Robichaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.